Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Eli Lilly & Co. has agreed to acquire Alnara, a privately held biotechnology company that develops protein therapeutics to treat metabolic diseases. “The acquisition of Alnara provides Lilly with a promising entry into enzyme replacement therapy,” says Bryce Carmine, president of Lilly BioMedicines. Alnara’s lead product, liprotamase, is a pancreatic enzyme replacement therapy that is under FDA review for the treatment of exocrine pancreatic insufficiency, a condition associated with cystic fibrosis and chronic pancreatitis.
This article has been sent to the following recipient: